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3 BP and ILSG contributed equally to this work.Arylamine N-acetyltransferases (NATs) are xenobiotic-metabolizing enzymes that biotransform
arylamine drugs. The Bacillus anthracis (BACAN)NAT1 enzyme affords increased resistance to the
antibiotic sulfamethoxazole through its acetylation. We report the structure of (BACAN)NAT1. Unex-
pectedly, endogenous coenzymeA was present in the active site. The structure suggests that, con-
trary to the other prokaryotic NATs, (BACAN)NAT1 possesses a 14-residue insertion equivalent to
the ‘‘mammalian insertion’’, a structural feature considered unique to mammalian NATs. Moreover,
(BACAN)NAT1 structure shows marked differences in the mode of binding and location of coenzy-
meA when compared to the other NATs. This suggests that the mechanisms of cofactor recognition
by NATs is more diverse than expected and supports the cofactor-binding site as being a unique sub-
site to target in drug design against bacterial NATs.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction common fold that comprises three domains and a cysteine prote-Arylamine N-acetyltransferases (NATs: EC 2.3.1.5) are a family
of enzymes that catalyze the acetylation of aromatic amines using
acetyl coenzyme A (AcCoA) [1,2]. In humans, NATs play an impor-
tant role in the detoxiﬁcation and/or bioactivation of numerous
drugs and xenobiotics [3]. These enzymes are found in a range of
eukaryotic and prokaryotic species [4–7] where they may play
diverse roles [6]. Determination of the structures of NATs has
helped to understand the catalytic mechanisms and functions of
these enzymes [6]. So far, the crystal structures of the two human
NAT isoenzymes and six prokaryotic NATs have been described
[8–14]. Moreover, the NMR structure of the Syrian Hamster
(MESAU)NAT2 has been reported [15]. These studies identiﬁed achemical Societies. Published by E
se; SMX, sulfamethoxazole;
alycilic acid; AcCoA, acetyl
ata Bank (PDB code 3LNB).
ris-diderot.fr (F. Rodrigues-
nada.
y, France.ase-like catalytic triad [6,16]. Although mammalian and prokary-
otic NATs share the same fold, differences at the amino acid
levels are known to have functional consequences [6,10,12,13,15].
Although the role of NAT in prokaryotes remains unclear, these
enzymes may contribute to adaptative and/or defense mechanisms
towards environmental toxins present in the habitats of bacteria
[6,17]. Certain bacterial NATs are able to acetylate various aromatic
amine antibiotics and increasing evidence suggests that these
enzymes could contribute to antibiotic resistance in bacteria such
as Mycobaterium tuberculosis [18,19]. In Bacillus anthracis, the
(BACAN)NAT1 isoenzyme (formerly known as BaNATC) acetylates
efﬁciently sulfamethoxazole and affords higher than normal resis-
tance to this antimicrobial when expressed in Escherichia coli [20].
Here we present the crystal structure of (BACAN)NAT1 in com-
plex with the cofactor coenzymeA. This novel NAT structure shows
marked differences in the mode of recognition and the location of
the cofactor compared to other prokaryotic and mammalian NAT
enzymes. Moreover, we show that (BACAN)NAT1 possesses a 14-
residues insertion equivalent to the ‘‘mammalian loop’’ found in
human isoenzymes. This loop is likely to contribute to the shape
of the active site cleft and subsequently to the recognition of the
cofactor by (BACAN)NAT1, as suggested for (HUMAN)NAT2
[12,13]. By demonstrating both unexpected structural similaritieslsevier B.V. All rights reserved.
Table 1
Data-collection and reﬁnement statistics for (BACAN)NAT1 crystal.
Crystallographic data quality
X-ray source ID23-1, ESRF Grenoble
Wavelength (Å) 0.92
Temperature (K) 100
Unit-cell parameters (Å, ) a = b = 53.99, c = 172.44
a = b = c = 90
Space group P41212
Resolution limits (Å) 50.0–2.0 (2.2–2.0)
Number of observations measured 17034 (3487)
I/r(I) 20.45 (7.91)
Rmerge
,§ (%) 6.3 (17.7)
Overall completeness(%) 94 (79.9)
Reﬁnement statistics
Number of non-hydrogen atoms (Protein/
Water/CoA/Other)
2055/137/48/6
Resolution range (Å) 45.8–2.0
R/Rfree (%) 20.3/24.4
R.M.S.D. bonds (Å)/angles () 0.06/1.3
Average B value-all (Å2) Protein/Water/CoA/
Other
18.85/23.68/20.26/25.06









iIhi, were Ihi is the ith observation of the reﬂection h,
while <Ih> is the mean intensity of reﬂection h.
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ing among different NAT enzymes, we provide a better under-
standing of the structures and functions of members within this
important family of xenobiotic-metabolizing enzymes.
2. Materials and methods
2.1. Materials
Unless otherwise stated all other reagents were from Sigma–
Aldrich.
2.2. Expression and puriﬁcation of (BACAN)NAT1
Recombinant (BACAN)NAT1 was expressed in E.coli BL21 (DE3)
and puriﬁed using nickel resin as described previously [20]. Puri-
ﬁed (BACAN)NAT1 was dialysed against 25 mM Tris–HCl pH 7.5,
1 mM EDTA and concentrated to 8 mg/ml using ultracentrifugation
concentrators (Amicon) [26].
2.3. Crystallization and data collection
Crystallization trials were performed at 294 K with AmSO4
Suite (Qiagen) and CrystalQuick microplates (Greiner). We used
the hanging-drop vapour-diffusion method by mixing 1.3 ll of
concentrated protein solution with 0.7 ll of reservoir solution.
Microcrystals were observed after two weeks with several solu-
tions (No. 23, 31, 37, 45). Using a mix of 2 ll of protein with 1 ll
of reservoir solution, the crystallization conditions were optimized
on EasyXtal Tools X-Seal (Qiagen) with 1.8 M ammonium sulphate
and 0.17 M potassium nitrate. Crystals, suitable for X-ray analysis,
grow in 5-7 days at a maximal size of 120  120  50 lm. They be-
longed to space group P41212. For cryoprotection, the crystal was
ﬁshed from the drop, put directly into sodium formate (7 M),
mounted in a cryoloop (Hampton Research) and immersed into li-
quid nitrogen prior to X-ray diffraction analysis.
Diffraction data were collected at 100 K on the beamline ID23-1
at the ESRF using a MAR CCD detector. We used an exposure time
of 0.1 s with a transmission of 16%. One thirty images were col-
lected with 1 oscillation per image at wavelength of 0.92 Å. The
data were subsequently processed with XDS [21]. The structure
of (BACAN)NAT1 protein was solved at 2 Å resolution by molecular
replacement, using the coordinates of Salmonella typhimurium NAT
(PDB entry:1E2T). The atomic coordinates and structure factors
have been deposited in the PDB with the accession code 3LNB.
The CCP4 Software Suite was used for the structure analysis [22].
2.4. High Performance Liquid Chromatography analysis
To detect the presence of CoA in the (BACAN)NAT1 samples
used for crystallisation, the protein samples were deproteinized
by perchlorate (100 ll of ice-cold aqueous perchlorate (15% w/v)
added to 100 ll of protein sample) and centrifugated (5 min at
12,000g). The molecules present in the supernatant (20 ll) were
identiﬁed by reverse-phase separation on a C18 column and Photo-
Diode Array (PDA) detection. Commercialy available CoA was used
as a standard.
3. Results and discussion
3.1. Overall structure
The multiple sequence alignment of (BACAN)NAT1 with several
structurally and functionally characterized NATs shows that
(BACAN)NAT1 shares around 30% and 20% amino acid sequenceidentity with bacterial and human NAT enzymes, respectively
(Figs. S1 and S2). (BACAN)NAT1 contains the characteristic con-
served NAT functional motifs described in all NAT enzymes charac-
terized so far [5,23]. Moreover, the alignments also suggests that
the (BACAN)NAT1 possesses an insertion of 14 amino acids at a po-
sition equivalent to the 17 amino acid insertion loop (known as the
‘‘mammalian insertion’’) which is considered to be speciﬁc of
mammalian NATs [12,15,23,24].
The (BACAN)NAT1 crystal structure was solved by molecular
replacement using the Salmonella typhimurium NAT structure and
reﬁned to 2 Å (Table 1). Clear electron density was present from
residues 1 to 167 and from residues 183 to 267. All residues but
one (Ala127) were in allowed regions of the Ramachandran plot
(data not shown). More importantly, an additional electron density
was found and identiﬁed as being coenzyme A (CoA) (Fig. 1). The
(BACAN)NAT1 structure resembles the overall fold of eukaryotic
and prokaryotic NATs [23] (Fig. 1). It consists of three domains of
similar size. Domain I is an a-helical bundle (amino acids 1–84).
The second domain forms a b-barrel (amino acids 85–196). The
structure of 15 residues (amino acids 168–182 which encompass
the 14-residues insertion) within domain II could not be deter-
mined due to lack of electron density. Domains I and II are dis-
posed in such a way that Cys70, His108 and Asp123 form the
catalytic triad (Fig. 1) [8]. The geometry of the catalytic residues
is conserved between (BACAN)NAT1 and the other NAT structures
with a RMSD around 0.1 Å. Domain III forms an a/b lid (amino
acids 198–267). This domain shows the most variation (both in
length and sequence) from the other NATs (Fig. S1) [23]. The sur-
face of these domains presents a deep and wide active-site pocket;
at the base of which the catalytic cysteine residue is found (Fig. 1).
The (BACAN)NAT1 structure differs from other bacterial enzymes
by RMSD values (ranging from 1.3 Å) over 183 and 217 residues
for (RHILO)NAT1 and (SALTY)NAT1, respectively. Although amino
acid sequence identity between (BACAN)NAT1 and human NATs
is only 20%, the structure of (BACAN)NAT1 displays RMSD values
of 1.4 Å over 215 residues with these enzymes.
3.2. Presence of a ‘‘mammalian-like’’ insertion in (BACAN)NAT1
Mammalian NATs are known to possess a 17-residue insertion
(‘‘mammalian insertion’’) which forms a loop between two
Fig. 1. X-ray crystal structure of (BACAN)NAT1. Left panel. Cartoon representation of the three-domains NAT fold of (BACAN)NAT1: helical bundle (domain I: 1-85), b-barrel
(domain II: 86–197) and a/b lid (domain III: 198–267), colored in red, yellow and blue, respectively. Residues of the catalytic triad Cys69-His108-Asp123 and the co-crystallized
CoA molecule are represented in sticks and electron density. b9 and b10 indicate the two b-strands ﬂanking the 15-residues electron density gap between residue Lys167 and
Asp183. Right panel. Surface representation of BaNAT C and bound CoA (sticks and electron density).
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Such an insertion is absent in the prokaryotic NAT structures re-
ported so far where the two equivalent b-strands (b8 and b9 in
(MYCMR)NAT1) are linked by a b-turn of 2–4 residues (Fig. 2)
[12,23]. (BACAN)NAT1 structure reveals that an insertion of 14-
amino acid (linking the b9 and b10) equivalent to the ‘‘mammalian
insertion’’ exists in domain II of this bacterial NAT [12,16,24].
Although no electron density could be obtained, this insertion
(spanning residues 169–182) is located between the b9 and b10
strands, which are structurally equivalent to b9 and b11 in (HU-Fig. 2. Structural comparison of the ‘‘mammalian insertion’’ region in (HUMAN)NAT2
residues corresponding to the eukaryotic insertion region of (HUMAN)NAT2, (BACAN)NA
Lower panels depict a focus on the ‘‘mammalian-like insertion’’ region of (BACAN)NAT1 (r
CoA shown in transparency. In (HUMAN)NAT2, this insertion corresponds to a 17-residu
not be modelled and are shown as one letter codes in brackets. No ‘‘mammalian-like inMAN)NAT2 (Fig. 2) [12]. The lack of electron density for this inser-
tion in (BACAN)NAT1 was also found in a second crystal form (with
characteristics similar to those of the crystal reported here i.e.
space group P41212; similar unit cell parameters; monomeric bio-
logical unit, tetragonal symmetry) (data not shown). This suggests
that the insertion is highly mobile and cannot be easily resolved. In
addition, SDS–PAGE and MALDI-TOF spectrometry analyses indi-
cate that the absence of electron density for the «insertion» is not
due to proteolysis. Indeed, all our SDS–PAGE analyses showed that
the majority of the protein had a molecular mass around 35 kDa., (BACAN)NAT1, and (MYCMR)NAT1. The three structures are superimposed and
T1 and (MYCMR)NAT1 are colored in green, red and blue respectively (upper panel).
ed), (HUMAN)NAT2 (green) and (MYCMR)NAT1 (blue), in the same orientation, with
es loop. The corresponding aligned residues (Gly168–Ser182) of (BACAN)NAT1 could
sertion’’ is present in (MYCMR)NAT1 where two strands are linked by a b-turn.
Fig. 3. Location and mode of recognition of CoA in (BACAN)NAT1, (HUMAN)NAT2 and (MYCMR)NAT1. A. Multiple amino acid sequence alignment of (BACAN)NAT1,
(HUMAN)NAT2 and (MYCMR)NAT1. Catalytic residues are shown by a star and the three conserved NAT domains are represented under the alignment by a red, yellow and
blue line, respectively. Residues interacting with the b-mercaptoethylamine, panthotenic acid or PPi-30ADP phosphate part of CoA are highlighted in yellow, magenta and
cyan, respectively. The green highlighted residue Phe216 of (BACAN)NAT1 interacts with both b-mercaptoethylamine and 30ADP phosphate part of CoA. Residues labeled with
a black triangle are involved in hydrophobic interactions, while the colored-only residues are forming hydrogen bonds with CoA. The structure of CoA is depicted in the lower
right panel. Catalytic residues are indicated by a star. B. Amino acids involved in CoA binding are represented by green sticks (one letter code). Hydrogen bonds are shown in
dots. The structure of each NAT is shown in transparency (white) and the catalytic residues are shown as white sticks. C. Surface representation of (BACAN)NAT1 (left),
(HUMAN)NAT2 (middle) and (MYCMR)NAT1 (right) with the same orientation. Co-crystallized CoA molecule orientation is divergent between (BACAN)NAT1 (red sticks),
HsNAT (green sticks) and (MYCMR)NAT1 (blue sticks). The catalytic cysteine is colored in yellow. The residues that ﬂank the ‘‘mammalian-like’’ insertion of (BACAN)NAT1
and the region corresponding to the loop are indicated in red (left). The region corresponding of the ‘‘mammalian insertion’’ in (HUMAN)NAT2 is indicated in green (middle).
The b-turn residues of (MYCMR)NAT1 linking the equivalent two b-strands that are linked by the insertion in (BACAN)NAT1 and human NAT2 are shown in blue.
3950 B. Pluvinage et al. / FEBS Letters 585 (2011) 3947–3952No fragments at 22 and 11 kDa (corresponding at the removal of
the insert by proteolysis) were observed. Secondly, MALDI-TOFspectrometry analyses of the protein in the crystal gave a major
peak at 35514.01 Da (the theoretical mass of the protein being
B. Pluvinage et al. / FEBS Letters 585 (2011) 3947–3952 395135493.6 Da) (data not shown). The function of the ‘‘mammalian
insertion’’ is not fully understood [12,24]. The structure of (HU-
MAN)NAT2 suggests that this insertion contributes to the shape
of the enzyme active site cleft and, subsequently, to the mode of
recognition of the enzyme cofactor AcCoA [12,13]. It may also con-
tribute to the stability of the enzyme by making several contacts
with other residues of the protein [12,24]. So far, (BACAN)NAT1
is the ﬁrst example of a bacterial NAT that possesses a ‘‘mamma-
lian-like’’ insertion.
3.3. Binding interactions and geometry of CoA in (BACAN)NAT1
As stated above, an unexpected additional electron density was
found in the active site of (BACAN)NAT1 (Fig. 1). This density was
identiﬁed as CoA, the non-acetylated form of AcCoA, which is the
cofactor used by NATs. This result was conﬁrmed in a second crys-
tal (data not shown) and indicated that (BACAN)NAT1 co-crystal-
lized with endogenous molecules of CoA that were «co-puriﬁed»
with the enzyme. The presence of CoA in the (BACAN)NAT1 protein
samples used for crystalisation was conﬁrmed by reverse phase
chromatography and the subsequent identiﬁcation of CoA by
Photo-Diode Array (PDA) spectroscopy (data not shown). Such an
approach allows the rapid and precise identiﬁcation of CoA based
both on its retention time and its UV/visible spectrum. These data
suggest that even after the puriﬁcation procedure (which includes
nickel-afﬁnity chromatography and dialysis), sufﬁcient amounts of
CoA are present in the protein samples to allow the crystallization
of (BACAN)NAT1 in complex with CoA. Although CoA is a product
of the NAT catalyzed reaction, it is known to bind to NATs and to
reduce their activity through competitive inhibition [23,25]. It is
likely that (BACAN)NAT1 is more prone to crystallization when
CoA is present thus explaining why only the holo-form of the en-
zyme was obtained. In addition, we found that (BACAN)NAT1 has
a Km,app for AcCoA equal to 50 lM (using 5-AS as a substrate) (data
not shown), which is four times lower than the Km,app, (determined
in the same conditions) for (MYCMR)NAT1 and the pseudomonas
aeruginosa NAT ((PSEAE)NAT1) [13]. Contrary to (BACAN)NAT1,
the other NAT-CoA cocrystals were obtained in presence of exoge-
nous CoA [12,13].
The CoA molecule in (BACAN)NAT1 structure is mainly bound
between domain II and III (Figs. 1 and 3). The binding of CoA to
(MYCMR)NAT1 and (HUMAN)NAT2 was also shown to involve pri-
marily domain II and III and similarities were indeed found with
our structure. Though several key differences were found as well
(Fig. 3). In (BACAN)NAT1, the majority of residues that intereact
with CoA are present in the b-sheet structure of the «a/b» lid
(Domain III: b11–b14). Although CoA interacts with the equivalent
b-sheet in (MYCMR)NAT1, it also interacts with additional residues
in two other b-sheets in domain II [13]. In (HUMAN)NAT2, the
residues interacting with CoA are mainly provided by a b-sheet
in domain II and by residues located in a-helices of domain III
[12,13]. As found in (MYCMR)NAT1 and (HUMAN)NAT2 structures,
several aromatic and aliphatic residues of (BACAN)NAT1 (such as
Phe38, Phe126, Ala127, Phe216 and Ile221) make an extensive
set of hydrophobic contacts throughout most of the length of the
b-mercaptoethylamine and panthotenic arms of CoA (Fig. 3A and
B) [12,13]. Moreover, in (BACAN)NAT1, six residues of the domain
III b-sheet (His230, Ser232, Thr234, Asn237, Lys246 and Lys248)
engage in several side-chain hydrogen bonds with oxygen atoms
of the phosphate groups in both the pyrophosphate and phosphate
30ADP moieties (Fig. 3A and B). Conversely, in (MYCMR)NAT1, only
one residue (Lys236) of the domain III b-sheet engages in a side-
chain hydrogen bond with a phosphate oxygen of the 30ADPmoiety
(Fig. 3A and B) [13]. In (HUMAN)NAT2, no residue in the domain III
b-sheet is involved in hydrogen bonding with CoA (Fig. 3A and B)
[12].The structure of (BACAN)NAT1 shows that three residues of the
structural ‘‘P-loop’’ (Phe126, Ala127 and Ser128) interact with CoA
(Fig. 3A and B) [8,23]. Similarly, ‘‘P-loop’’ residues are also involved
in CoA binding in (MYCMR)NAT1 [13]. However, none of these
‘‘P-loop’’ residues of (BACAN)NAT1 interact with the phosphate
oxygen atoms of CoA, as it had been predicted [8,13]. Also, in
(HUMAN)NAT2, no interactions between the ‘‘P-loop’’ structure
and the cofactor were found [12]. The recognition of the adenine
moiety of CoA in (BACAN)NAT1 is only achieved by hydrophobic
contacts (contributed by Phe38, Phe216 and Ile221) whereas in
(MYCMR)NAT1 and (HUMAN)NAT2 this recognition occurs
through both hydrophobic and hydrogen bonds (Fig. 3B) [12, 13].
Parts of CoA sits similarly in the cleft in (BACAN)NAT1,
(MYCMR)NAT1 and (HUMAN)NAT2 such that the catalytic cysteine
is close to the b-mercaptoethylamine group of CoA. Though the
distal region of the cofactor interacts differently with the respec-
tive NATs (Figs. S3 and 3C and Table S1) [12,13]. This leads to
marked differences in the geometry of CoA bound to the different
enzymes (Figs. S3 and 3C and Table S1). In (BACAN)NAT1, the phos-
phate groups of the pyrophosphate segment introduce a sharp
bends into the CoA molecule as a result of steric interactions be-
tween CoA and the side-chains in this region of the active site of
(BACAN)NAT1 (Figs. S3 and 3C and Table S1).
In (MYCMR)NAT1 structure, the CoA molecule ﬁts into an ex-
tended cleft that stretches for 21 Å (from the active site cysteine
to the N6 atome of adenine) and over a surface of 1560 Å2
(Fig. 3C) [13]. In (BACAN)NAT1 and (HUMAN)NAT2, the cofactor
ﬁts in an equivalent but narrower cleft that stretches for 15.9
and 9.4 Å (for (HUMAN)NAT2 and (BACAN)NAT1, respectively)
over a surface of 1100 Å2 (Fig. 3C). It has been shown that such
a difference in the location and mode of binding of CoA between
(MYCMR)NAT1 and (HUMAN)NAT2 is due to the shape of the cleft
where the cofactor binds and, in particular, to the existence in
(HUMAN)NAT2 of the ‘‘mammalian insertion.’’ This precludes a
shared mechanism of recognition of the nucleosidephosphate
portion of CoA in the two NAT enzymes [13]. Although, the
‘‘mammalian-like’’ insertion in not observable in our (BACAN)-
NAT1 structure, our data strongly suggests that this extended
loop also contributes to the mode of recognition and to the loca-
tion of CoA in (BACAN)NAT1 (Figs. 1 and 3C) [13]. Taken together,
our results on (BACAN)NAT1 and the previously published CoA–
NAT structures indicate that cofactor recognition by prokaryotic
and eukaryotic NAT enzymes is likely to be more diverse than
previously expected [13]. This may reﬂect the differing evolution-
ary pressures on NATs specialized for their respective roles in
prokaryotes and eukaryotes.
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